Please login to the form below

Not currently logged in

Dr Richard Barker joins Celgene's board of directors

Former ABPI director general takes up second new post this month

Richard Barker - CelgeneFormer director general of the Association of the British Pharmaceutical Industry (ABPI) Dr Richard Barker has been elected to the board of directors at Celgene.

He spent almost seven years at ABPI's helm, stepping down in May last year when he was succeeded by Stephen Whitehead.

It is Barker's second recent appointment after he joined authentication and traceability services company Aegate earlier this month as a senior adviser.

Prior to his post leading the ABPI, Barker's career included serving as chief executive of Chiron Diagnostics, general manager of IBM's Worldwide Healthcare Solutions division and leader of McKinsey & Company's European healthcare practice.

Robert Hugin, Celgene's chairman and CEO, said: “As we continue to expand our global reach, Dr Barker's international perspective will enhance our ability to navigate through an increasingly dynamic healthcare landscape and provide patients access to our innovative therapies.”

The US biopharmaceutical company focuses on developing and commercialising novel treatments for cancer and inflammatory diseases.

Its top-selling product is Revlimid, which suffered a setback last November after a phase III prostate cancer trial found no overall survival benefit.

Nevertheless, the drug is still expected to account for around $3bn of the firm's 2011 sales.

24th January 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...